Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma | OncLive

Dr. Kumar on Potential of CAR T-Cell Therapy in Multiple Myeloma

May 2, 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the field of multiple myeloma.

The potential of CAR T-cell therapy depends on the results that stem from ongoing clinical trials exploring this type of treatment in these patients, Kumar says. It is too early to speak to the efficacy of CAR T-cell therapy, as well as the immunotherapy agents being studied. Moreover, the toxicity profile has been found to be high in many patients.

Because of the associated toxicities, this may not be the ideal treatment to use in the upfront setting, he adds.


x